Lucid Diagnostics (NASDAQ:LUCD) Posts Quarterly Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) released its quarterly earnings data on Tuesday. The company reported ($0.26) EPS for the quarter, Yahoo Finance reports. The business had revenue of $1.04 million for the quarter. Lucid Diagnostics had a negative net margin of 2,169.07% and a negative return on equity of 8,334.14%. During the same quarter in the previous year, the business posted ($0.22) earnings per share.

Lucid Diagnostics Stock Performance

Lucid Diagnostics stock opened at $0.99 on Thursday. Lucid Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $1.85. The firm’s fifty day moving average price is $1.29 and its 200-day moving average price is $1.34.

Institutional Trading of Lucid Diagnostics

A number of institutional investors have recently made changes to their positions in LUCD. BlackRock Inc. boosted its holdings in shares of Lucid Diagnostics by 18.7% during the first quarter. BlackRock Inc. now owns 67,565 shares of the company’s stock worth $227,000 after purchasing an additional 10,636 shares during the period. Vanguard Group Inc. lifted its position in shares of Lucid Diagnostics by 25.6% in the 1st quarter. Vanguard Group Inc. now owns 312,876 shares of the company’s stock worth $1,051,000 after purchasing an additional 63,687 shares during the period. Verition Fund Management LLC bought a new position in Lucid Diagnostics in the first quarter worth about $122,000. State Street Corp lifted its holdings in Lucid Diagnostics by 24.4% in the first quarter. State Street Corp now owns 56,693 shares of the company’s stock worth $190,000 after buying an additional 11,121 shares during the period. Finally, Geneos Wealth Management Inc. bought a new stake in Lucid Diagnostics during the 1st quarter valued at approximately $209,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Analyst Upgrades and Downgrades

LUCD has been the subject of several analyst reports. Cantor Fitzgerald cut their target price on Lucid Diagnostics from $3.80 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $2.50 price target on shares of Lucid Diagnostics in a report on Wednesday.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.